ACRV
Acrivon Therapeutics, Inc.
Biotechnology · Healthcare · United States
1.66
close · 2026-10-30
value
12
cheaper than peers12
quality
54
stronger fundamentals54
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.82× | 87 |
| EV to EBITDA | 0.27× | 69 |
| cash flow yield, 3 years ago | -45.4% | 23 |
| earnings yield, 2 years ago | -165.1% | 21 |
| cash flow yield, 2 years ago | -61.8% | 20 |
| earnings yield, latest year | -121.7% | 17 |
| earnings yield, 1 year ago | -143.4% | 16 |
| cash flow yield, latest year | -91.8% | 12 |
| cash flow yield, 1 year ago | -96.2% | 12 |
| earnings yield, 3 years ago | -455.4% | 5 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 2.5% | 57 |
| return on equity | -60.4% | 52 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $71M |
| free cash flow | -$40.9M |
| employees | 74 |
| first trade | 2022-11-15 |
| next earnings | not reported |
| fundamentals updated | 2026-08-13 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -2.02 | -2.38 | -2.74 | -7.56 | not reported |
| free cash flow | -$65.3M | -$68.4M | -$43.9M | -$32.3M | not reported |
| net income | -$77.9M | -$80.6M | -$60.4M | -$31.2M | not reported |
| revenue | $0 | $0 | $0 | $0 | not reported |
| unusual items | not reported | not reported | not reported | not reported | -$80,000 |